Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) Short Interest Down 84.8% in June

Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) saw a significant decrease in short interest in June. As of June 30th, there was short interest totaling 143,052 shares, a decrease of 84.8% from the June 15th total of 942,551 shares. Based on an average daily volume of 1,785,958 shares, the days-to-cover ratio is presently 0.1 days. Currently, 12.1% of the shares of the company are sold short.

Regentis Biomaterials Stock Down 8.4%

Shares of NYSEAMERICAN RGNT traded down $0.32 during midday trading on Monday, reaching $3.47. 71,522 shares of the company traded hands, compared to its average volume of 10,284,606. The stock’s 50-day moving average is $2.98. Regentis Biomaterials has a 52 week low of $1.23 and a 52 week high of $15.50.

Institutional Trading of Regentis Biomaterials

An institutional investor recently bought a new position in Regentis Biomaterials stock. AIGH Capital Management LLC acquired a new stake in Regentis Biomaterials Ltd. (NYSEAMERICAN:RGNT) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 300,000 shares of the company’s stock, valued at approximately $916,000. AIGH Capital Management LLC owned approximately 5.79% of Regentis Biomaterials at the end of the most recent reporting period.

Regentis Biomaterials Company Profile

Regentis Biomaterials Ltd. is a regenerative medicine company dedicated to developing tissue repair solutions which seek to restore the health. Regentis Biomaterials Ltd. is based in Herzliya, Israel.